Archive for year: 2021

Cambridge, UK, 30 April 2021 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been highly commended in the “Life Science Company of the Year” category at the 4th Cambridge Independent Science and Technology Awards.

The Company was recognised for its transformational technology and significant progress over the past year. Recent achievements include a key new strategic collaboration with Cancer Research UK and Cambridge University Hospitals, progressing lead programmes in ulcerative colitis and immuno-oncology towards the clinic, and moving into purpose-configured facilities at Chesterford Research Park.

Mike Romanos, CEO of Microbiotica, said: “We are proud to be recognised for the milestones we have achieved this past year. Despite challenging conditions, we have progressed our ongoing programmes, expanded and strengthened our team, signed a key strategic collaboration, and moved to our new facility in Chesterford Research Park, so we can now house all our scientists in the same building for the first time. I would like to congratulate all the winners and highly commended entries and thank the entire Microbiotica team for their continued efforts.”

The Cambridge Independent Science and Technology Awards recognise outstanding life science and biotechnology companies in Cambridge. The ceremony took place virtually in a bespoke interactive environment, and was attended by leaders of businesses, organisations and research institutes across the Cambridge region on April 15, 2021.

-ENDS-

Contact:

Microbiotica:
Ro Gardner
T: +44 1223 786063 / M: +44 7801 480569
E: rgardner@microbiotica.com

Microbiotica (Media relations):
Melanie Toyne-Sewell / Agnes Stephens / Phil Marriage / Nathan Billis
T: +44 20 7457 2020
E : microbiotica@instinctif.com

 

NOTES TO EDITORS

About Microbiotica

Microbiotica is a leading player in the field of microbiome-based therapeutics, biomarkers and targets. The Company is building a growing pipeline of best-in-class differentiated products based on high quality clinical datasets and unique bacterial signatures that drive biology, identified by its proprietary platform.

Consisting of the world’s leading microbiome Reference Genome Database, Culture Collection, mass culturing technology (Personalised Bacterial Bank) and proprietary AI tools, Microbiotica’s platform enables unrivalled strain-level microbiome analysis linked to patient phenotypes. The Company’s current therapeutic areas of focus are immuno-oncology and IBD, and it has established major clinical and academic partnerships, including a $534m collaboration with Genentech.

Spun out of the Sanger Institute in 2016 by Dr Mike Romanos, Dr Trevor Lawley and Professor Gordon Dougan, the Company is based at Chesterford Research Park near Cambridge, UK. Microbiotica’s investor syndicate includes Cambridge Innovation Capital, IP Group plc and Seventure Partners.

For more information, please visit www.microbiotica.com, LinkedIn and Twitter.

All staff under one roof, at state-of-the-art office and laboratory space

Cambridge, UK, 19 April 2021 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has finalised its move to purpose-configured facilities at Chesterford Research Park, to accommodate its long-term growth requirements.

The Company’s operations were previously split between the Sulston Building and the BioData Innovation Centre at the Wellcome Genome Campus, before expansion into additional space within Chesterford Research Park’s Science Village in November 2019. Microbiotica’s move into the purpose-configured building brings the entire team under one roof in state-of-the-art office and laboratory space.

The move follows another year of significant progress for Microbiotica in using its world-leading platform to explore the microbiome as a new class of medicine. Most recently, Microbiotica entered a landmark collaboration in immuno-oncology with Cancer Research UK and Cambridge University Hospitals to develop microbiome co-therapeutics and biomarkers for cancer patients receiving checkpoint inhibitor therapy. In addition, the Company has existing programs in IBD and immuno-oncology, and major partnerships with the University of Adelaide and Genentech.

Dr Mike Romanos, CEO of Microbiotica, said:

 “We are delighted to have moved into our new building at Chesterford Research Park, Cambridge. Although some of our team are currently temporarily working at home because of pandemic-related restrictions, this move means that our whole team will soon be working under one roof for the first time. The larger, state-of-the-art facilities will allow us maintain the momentum we have achieved over the past few years and provide us with a strong foundation for the Company’s next stage of development, as we take our exciting Immuno-oncology and IBD products, derived from clinical data, into the clinic.”

“I would like to thank the whole team for all their hard work during this move and for making the transition as seamless as possible, particularly during these challenging times. I’m looking forward to us all being together in the Company’s new home in the near future.”